Ovoca Bio PLC - Interim Results
Ovoca Bio plc
("Ovoca" or the "Company")
Interim Results for the six months ended
Please click on the following link to view the full Half Year Report:
http://www.rns-pdf.londonstockexchange.com/rns/6341L_1-2021-9-13.pdf
Highlights:
· More than 50 per cent. of patients enrolled in the Phase II dose ranging study assessing BP-101 being conducted in
· Following a publication in the World Health Organization's International Non-proprietary Names for Pharmaceutical Substances, BP-101 will now be referred to as "orenetide"
· Marketing Authorisation ("MA") application for orenetide updated and refiled with the Russian Ministry of Health (the "Minzdrav") and a decision is expected by the end of 2021
· Investment in a new manufacturing process and source in
·
Letter from the CEO
During the period, Ovoca has maintained its focus on the development of novel treatments in areas of unmet medical need in the women's health sector, continuing to make progress in the development of BP-101, a first-in-class treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire.
We are pleased to report that following a publication in the World Health Organization's International Non-proprietary Names for Pharmaceutical Substances, orenetide has been confirmed as the new generic name for BP-101. This recognition by the WHO marks a welcome step forward for Ovoca as we await a decision from the Russian Ministry of Health (Minzdrav) on approval of the product in the
In
A previous MA submission filed with the Minzdrav in
With respect to development for more profitable international markets, in
In parallel with our clinical development activities, we are collaborating with one of the leading European peptide manufacturers to produce orenetide under an improved manufacturing process. In the short term, this is intended to deliver sufficient material to support the upcoming long-term toxicological assessments, as required by the US Food and Drug Association and regulatory authorities in
With few treatments available, there remains a high unmet medical need for patients suffering from hypoactive sexual desire disorder (HSDD), one of the most common female sexual problems globally, with an estimated one in ten premenopausal women affected. As previously reported, having reviewed clinical data from the Phase II and Phase III trials conducted in
We are pleased to note also that the business retains a firm capital base, with
End
For further information:
Ovoca Bio plc
Tel +353 1 661 9819
Davy (Nominated Adviser, Euronext Growth Advisor and Broker)
Tel: +353 1 679 6363
Consilium Strategic Communications
Tel: +44 (0)20 3709 5700
About Ovoca Bio
Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD).
The Company's lead product, orenetide (also referred to as BP-101), a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in
Ovoca Bio is seeking to develop the drug for major global markets - in particular
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE